Lighting the fires within: the cell biology of autoinflammatory diseases

Nature Reviews Immunology

Volumn 12, Issue 8, 2012, Pages 570-580

  Park, Heiyoung ^a,c   Bourla, Ariel Bulua ^a   Kastner, Daniel L ^b   Colbert, Robert A ^a   Siegel, Richard M ^a  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRYOPYRIN; HLA B27 ANTIGEN; TUMOR NECROSIS FACTOR RECEPTOR 1; X BOX BINDING PROTEIN 1;

AUTOINFLAMMATORY DISEASE; BLAU SYNDROME; CANDLE SYNDROME; CELL MIGRATION; CINCA SYNDROME; CYTOLOGY; DISEASE ASSOCIATION; FAMILIAL MEDITERRANEAN FEVER; HUMAN; HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME; INNATE IMMUNITY; JMP SYNDROME; NAKAJO NISHIMURA SYNDROME; NONHUMAN; OLIGOMERIZATION; PAPA SYNDROME; PRIORITY JOURNAL; PROTEIN FOLDING; PSORIASIS; PUSTULAR PSORIASIS; REVIEW; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME;

ANIMALS; AUTOIMMUNE DISEASES; ENDOPLASMIC RETICULUM STRESS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; RHEUMATIC DISEASES;

EID: 84864345963     PISSN: 14741733     EISSN: 14741741     Source Type: Journal    
DOI: 10.1038/nri3261     Document Type: Review

References (105)

1. McGonagle, D. & McDermott, M. F. A proposed classification of the immunological diseases. PLoS Med. 3, e297 (2006).
2. Masters, S. L., Simon, A., Aksentijevich, I. & Kastner, D. L. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu. Rev. Immunol. 27, 621-668 (2009).
3. Martinon, F., Petrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237-241 (2006). (Pubitemid 43372104)
4. Schroder, M. & Kaufman, R. J. ER stress and the unfolded protein response. Mutat. Res. 569, 29-63 (2005). (Pubitemid 39643256)
5. Pipe, S. W. & Kaufman, R. J. Factor VIII C2 domain missense mutations exhibit defective trafficking of biologically functional proteins. J. Biol. Chem. 271, 25671-25676 (1996). (Pubitemid 26337948)
6. Kopito, R. R. Biosynthesis and degradation of CFTR. Physiol. Rev. 79, S167-S173 (1999). (Pubitemid 29058913)
7. Oyadomari, S. et al. Targeted disruption of the Chop gene delays endoplasmic reticulum stress-mediated diabetes. J. Clin. Invest. 109, 525-532 (2002). (Pubitemid 34171784)
8. Wang, J. et al. A mutation in the insulin 2 gene induces diabetes with severe pancreatic β-cell dysfunction in the Mody mouse. J. Clin. Invest. 103, 27-37 (1999). (Pubitemid 29031160)
9. Datta, R., Waheed, A., Bonapace, G., Shah, G. N. & Sly, W. S. Pathogenesis of retinitis pigmentosa associated with apoptosis-inducing mutations in carbonic anhydrase IV. Proc. Natl Acad. Sci. USA 106, 3437-3442 (2009).
10. Harraz, M. M. et al. SOD1 mutations disrupt redox-sensitive Rac regulation of NADPH oxidase in a familial ALS model. J. Clin. Invest. 118, 659-670 (2008). (Pubitemid 351206555)
11. Urano, F. et al. Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science 287, 664-666 (2000). (Pubitemid 30070916)
12. Zhang, K. et al. Endoplasmic reticulum stress activates cleavage of CREBH to induce a systemic inflammatory response. Cell 124, 587-599 (2006). (Pubitemid 43199443)
13. Martinon, F., Chen, X., Lee, A. H. & Glimcher, L. H. TLR activation of the transcription factor XBP1 regulates innate immune responses in macrophages. Nature Immunol. 11, 411-418 (2010).
14. Masters, S. L. et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nature Immunol. 11, 897-904 (2010).
15. Halle, A. et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-β. Nature Immunol. 9, 857-865 (2008).
16. Kastner, D., Aksentijevich, I. & Goldbach-Mansky, R. Autoinflammatory disease reloaded: a clinical perspective. Cell 140, 784-790 (2010).
17. Jordan, C. T. et al. PSORS2 is due to mutations in CARD14. Am. J. Hum. Genet. 90, 784-795 (2012).
18. Jordan, C. T. et al. Rare and common variants in CARD14, encoding an epidermal regulator of NF-κB, in psoriasis. Am. J. Hum. Genet. 90, 796-808 (2012).
19. Agarwal, A. K. et al. PSMB8 encoding the β5i proteasome subunit is mutated in joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy syndrome. Am. J. Hum. Genet. 87, 866-872 (2010).
20. Arima, K. et al. Proteasome assembly defect due to a proteasome subunit β type 8 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome. Proc. Natl Acad. Sci. USA 108, 14914-14919 (2011).
21. Kitamura, A., et al. A mutation in the immunoproteasome subunit PSMB8 causes autoinflammation and lipodystrophy in humans. J. Clin. Invest. 121, 4150-4160 (2011).
22. Liu, Y. et al. Mutations in PSMB8 cause CANDLE syndrome with evidence of genetic and phenotypic heterogeneity. Arthritis Rheum. (in the press).
23. Aksentijevich, I. et al. The clinical continuum of cryopyrinopathies: novel cias1 mutations in north american patients and a new cryopyrin model. Arthritis Rheum. 56, 1273-1285 (2007). (Pubitemid 46608652)
24. Strowig, T., Henao-Mejia, J., Elinav, E. & Flavell, R. Inflammasomes in health and disease. Nature 481, 278-286 (2012).
25. Henao-Mejia, J. et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482, 179-185 (2012).
26. Elinav, E. et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 145, 745-757 (2011).
27. Chen, G. Y., Liu, M., Wang, F., Bertin, J. & Nunez, G. A functional role for Nlrp6 in intestinal inflammation and tumorigenesis. J. Immunol. 186, 7187-7194 (2011).
28. Eisenbarth, S. C. & Flavell, R. A. Innate instruction of adaptive immunity revisited: the inflammasome. EMBO Mol. Med. 1, 92-98 (2009).
29. Jeru, I., Hayrapetyan, H., Duquesnoy, P., Sarkisian, T. & Amselem, S. PYPAF1 nonsense mutation in a patient with an unusual autoinflammatory syndrome: role of PYPAF1 in inflammation. Arthritis Rheum. 54, 508-514 (2006). (Pubitemid 43228626)
30. Tanaka, N. et al. High incidence of NLRP3 somatic mosaicism in patients with chronic infantile neurologic, cutaneous, articular syndrome: results of an International Multicenter Collaborative Study. Arthritis Rheum. 63, 3625-3632 (2011).
31. Kanneganti, T. D., Lamkanfi, M. & Nunez, G. Intracellular NOD-like receptors in host defense and disease. Immunity 27, 549-559 (2007). (Pubitemid 47615512)
32. Pelegrin, P. & Surprenant, A. Pannexin-1 mediates large pore formation and interleukin-1β release by the ATP-gated P2X7 receptor. EMBO J. 25, 5071-5082 (2006). (Pubitemid 44658525)
33. Marina-Garcia, N. et al. Pannexin-1-mediated intracellular delivery of muramyl dipeptide induces caspase-1 activation via cryopyrin/NLRP3 independently of Nod2. J. Immunol. 180, 4050-4057 (2008).
34. Sharp, F. A. et al. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc. Natl Acad. Sci. USA 106, 870-875 (2009).
35. Hornung, V. et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nature Immunol. 9, 847-856 (2008).
36. Dostert, C. et al. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 320, 674-677 (2008). (Pubitemid 351928351)
37. Parikh, H. et al. TXNIP regulates peripheral glucose metabolism in humans. PLoS Med. 4, e158 (2007).
38. Zhou, R., Tardivel, A., Thorens, B., Choi, I. & Tschopp, J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nature Immunol. 11, 136-140 (2009).
39. Menu, P. et al. ER stress activates the NLRP3 inflammasome via an UPR-independent pathway. Cell Death Dis. 3, e261 (2012).
40. Petrilli, V. et al. Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ. 14, 1583-1589 (2007). (Pubitemid 47278844)
41. Cruz, C. M. et al. ATP activates a reactive oxygen species-dependent oxidative stress response and secretion of proinflammatory cytokines in macrophages. J. Biol. Chem. 282, 2871-2879 (2007). (Pubitemid 47084344)
42. Tassi, S. et al. Altered redox state of monocytes from cryopyrin-associated periodic syndromes causes accelerated IL-1β secretion. Proc. Natl Acad. Sci. USA 107, 9789-9794 (2010).
43. Bulua, A. C. et al. Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS). J. Exp. Med. 208, 519-533 (2011).
44. Pollock, J. D. et al. Mouse model of X-linked chronic granulomatous disease, an inherited defect in phagocyte superoxide production. Nature Genet. 9, 202-209 (1995).
45. van de Veerdonk, F. L. et al. Reactive oxygen species-independent activation of the IL-1β inflammasome in cells from patients with chronic granulomatous disease. Proc. Natl Acad. Sci. USA 107, 3030-3033 (2010).
46. Meissner, F. et al. Inflammasome activation in NADPH oxidase defective mononuclear phagocytes from patients with chronic granulomatous disease. Blood 116, 1570-1573 (2010).
47. Zhou, R., Yazdi, A. S., Menu, P. & Tschopp, J. A role for mitochondria in NLRP3 inflammasome activation. Nature 469, 221-225 (2010).
48. Saitoh, T. et al. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1β production. Nature 456, 264-268 (2008).
49. Shimada, K. et al. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity 36, 401-414 (2012).
50. Bauernfeind, F. et al. Cutting edge: reactive oxygen species inhibitors block priming, but not activation, of the NLRP3 inflammasome. J. Immunol. 187, 613-617 (2011).
51. Touitou, I. (ed.) Infevers: the registry of hereditary auto-inflammatory disorders mutations online, http://fmf.igh.cnrs.fr/ISSAID/infevers (2012).
52. Duncan, J. A. et al. Cryopyrin/NALP3 binds ATP/dATP, is an ATPase, and requires ATP binding to mediate inflammatory signaling. Proc. Natl Acad. Sci. USA 104, 8041-8046 (2007). (Pubitemid 47185872)
53. McDermott, M. F. et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 97, 133-144 (1999). (Pubitemid 29165896)
54. Hull, K. M. et al. The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine 81, 349-368 (2002).
55. Kimberley, F. C., Lobito, A. A., Siegel, R. M. & Screaton, G. R. Falling into TRAPS-receptor misfolding in the TNF receptor 1-associated periodic fever syndrome. Arthritis Res. Ther. 9, 217 (2007).
56. Stojanov, S. et al. Clinical and functional characterisation of a novel TNFRSF1A c.605T>A/V173D cleavage site mutation associated with tumour necrosis factor receptor-associated periodic fever syndrome (TRAPS), cardiovascular complications and excellent response to etanercept treatment. Ann. Rheum. Dis. 67, 1292-1298 (2008).
57. Bulua, A. C. et al. Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome (TRAPS). Arthritis Rheum. 64, 908-913 (2011).
58. Lobito, A. A. et al. Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS). Blood 108, 1320-1327 (2006). (Pubitemid 44232031)
59. Todd, I. et al. Mutant tumor necrosis factor receptor associated with tumor necrosis factor receptor-associated periodic syndrome is altered antigenically and is retained within patients' leukocytes. Arthritis Rheum. 56, 2765-2773 (2007). (Pubitemid 47237296)
60. Rebelo, S. L. et al. Modeling of tumor necrosis factor receptor superfamily 1A mutants associated with tumor necrosis factor receptor-associated periodic syndrome indicates misfolding consistent with abnormal function. Arthritis Rheum. 54, 2674-2687 (2006). (Pubitemid 44205030)
61. Simon, A. et al. Concerted action of wild-type and mutant TNF receptors enhances inflammation in TNF receptor 1-associated periodic fever syndrome. Proc. Natl Acad. Sci. USA 107, 9801-9806 (2010).
62. Dickie, L. J. et al. Involvement of X-box binding protein 1 and reactive oxygen species pathways in the pathogenesis of tumour necrosis factor receptor-associated periodic syndrome. Ann. Rheum. Dis. 7 Jun 2012 (doi:10.1136/annrheumdis-2011-201197).
63. The International FMF Consortium. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 90, 797-807 (1997).
64. Chae, J. J. et al. Isolation, genomic organization, and expression analysis of the mouse and rat homologs of MEFV, the gene for familial mediterranean fever. Mamm. Genome 11, 428-435 (2000). (Pubitemid 30407405)
65. Yu, J.-W. et al. Cryopyrin and pyrin activate caspase-1, but not NF-κB, via ASC oligomerization. Cell Death Differ. 13, 236-249 (2006). (Pubitemid 43102207)
66. Seshadri, S., Duncan, M. D., Hart, J. M., Gavrilin, M. A. & Wewers, M. D. Pyrin levels in human monocytes and monocyte-derived macrophages regulate IL-1β processing and release. J. Immunol. 179, 1274-1281 (2007).
67. Chae, J. J. et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1β production. Proc. Natl Acad. Sci. USA 103, 9982-9987 (2006). (Pubitemid 43993609)
68. Papin, S. et al. The SPRY domain of Pyrin, mutated in familial Mediterranean fever patients, interacts with inflammasome components and inhibits proIL-1β processing. Cell Death Differ. 14, 1457-1466 (2007). (Pubitemid 47096500)
69. Chae, J. J. et al. Gain-of-function Pyrin mutations induce NLRP3 protein-independent interleukin-1β activation and severe autoinflammation in mice. Immunity 34, 755-768 (2011).
70. Booty, M. G. et al. Familial Mediterranean fever with a single MEFV mutation: where is the second hit? Arthritis Rheum. 60, 1851-1861 (2009).
71. Braun, J. & Sieper, J. Ankylosing spondylitis. Lancet 369, 1379-1390 (2007). (Pubitemid 46590387)
72. Ambarus, C., Yeremenko, N., Tak, P. P. & Baeten, D. Pathogenesis of spondyloarthritis: autoimmune or autoinflammatory? Curr. Opin. Rheumatol. 24, 351-358 (2012).
73. Smith, J. A., Marker-Hermann, E. & Colbert, R. A. Pathogenesis of ankylosing spondylitis: current concepts. Best Pract. Res. Clin. Rheumatol. 20, 571-591 (2006). (Pubitemid 44182767)
74. Turner, M. J., Delay, M. L., Bai, S., Klenk, E. & Colbert, R. A. HLA-B27 up-regulation causes accumulation of misfolded heavy chains and correlates with the magnitude of the unfolded protein response in transgenic rats: implications for the pathogenesis of spondylarthritis-like disease. Arthritis Rheum. 56, 215-223 (2007). (Pubitemid 46106195)
75. Turner, M. J. et al. HLA-B27 misfolding in transgenic rats is associated with activation of the unfolded protein response. J. Immunol. 175, 2438-2448 (2005). (Pubitemid 41113854)
76. Smith, J. A. et al. Endoplasmic reticulum stress and the unfolded protein response are linked to synergistic IFN-β induction via X-box binding protein 1. Eur. J. Immunol. 38, 1194-1203 (2008).
77. DeLay, M. L. et al. HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats. Arthritis Rheum. 60, 2633-2643 (2009).
78. Goodall, J. C. et al. Endoplasmic reticulum stress-induced transcription factor, CHOP, is crucial for dendritic cell IL-23 expression. Proc. Natl Acad. Sci. USA 107, 17698-17703 (2010).
79. Burton, P. R. et al. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447, 661-678 (2007). (Pubitemid 46889737)
80. Griffin, T. A. & Reed, A. M. Pathogenesis of myositis in children. Curr. Opin. Rheumatol. 19, 487-491 (2007). (Pubitemid 47344243)
81. Liao, A. P. et al. Interferon β is associated with type 1 interferon-inducible gene expression in dermatomyositis. Ann. Rheum. Dis. 70, 831-836 (2011).
82. Tournadre, A., Lenief, V., Eljaafari, A. & Miossec, P. Immature muscle precursors are a source of interferon-β in myositis: role of Toll-like receptor 3 activation and contribution to HLA class I up-regulation. Arthritis Rheum. 64, 533-541 (2012).
83. Nagaraju, K. et al. Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc. Natl Acad. Sci. USA 97, 9209-9214 (2000). (Pubitemid 30626699)
84. Todd, D. J., Lee, A. H. & Glimcher, L. H. The endoplasmic reticulum stress response in immunity and autoimmunity. Nature Rev. Immunol. 8, 663-674 (2008).
85. Kaser, A. et al. XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell 134, 743-756 (2008).
86. Iwakoshi, N. N. et al. Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1. Nature Immunol. 4, 321-329 (2003). (Pubitemid 36432313)
87. Seifert, U. et al. Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress. Cell 142, 613-624 (2010).
88. Goldbach-Mansky, R. et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1β inhibition. N. Engl. J. Med. 355, 581-592 (2006). (Pubitemid 44200651)
89. Hoffman, H. M. et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 364, 1779-1785 (2004). (Pubitemid 39488063)
90. Sibley, C. H. et al. Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three-and five-year outcomes. Arthritis Rheum. 64, 2375-2386 (2012).
91. Dinarello, C. A. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117, 3720-3732 (2011).
92. Schumacher, H. R. Jr et al. Rilonacept (Interleukin-1 Trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results of the presurge-1 trial. Arthritis Care Res. 1 May 2012 (doi:10.1002/acr.21690).
93. So, A. et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum. 62, 3064-3076 (2010).
94. Larsen, C. M. et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 356, 1517-1526 (2007). (Pubitemid 46588416)
95. Larsen, C. M. et al. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 32, 1663-1668 (2009).
96. Pascual, V., Allantaz, F., Arce, E., Punaro, M. & Banchereau, J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J. Exp. Med. 201, 1479-1486 (2005). (Pubitemid 40664091)
97. Lequerre, T. et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann. Rheum. Dis. 67, 302-308 (2008). (Pubitemid 351281262)
98. Drenth, J. P. et al. Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. Nature Genet. 22, 178 (1999).
99. Feldmann, J. et al. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am. J. Hum. Genet. 71, 198-203 (2002). (Pubitemid 34734724)
100. Aksentijevich, I. et al. The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum. 56, 1273-1285 (2007). (Pubitemid 46608652)
101. Rose, C., Martin, T. & Wouters, C. Blau syndrome revisited. Curr. Opin. Rheumatol. 23, 411-418 (2011).
102. Miceli-Richard, C. et al. CARD15 mutations in Blau syndrome. Nature Genet. 29, 19-20 (2001). (Pubitemid 32801800)
103. Shoham, N. G. et al. Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc. Natl Acad. Sci. USA 100, 13501-13506 (2003). (Pubitemid 37444771)
104. Aksentijevich, I. et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N. Engl. J. Med. 360, 2426-2437 (2009).
105. Marrakchi, S. et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N. Engl. J. Med. 365, 620-628 (2011).